Unresolved
We still don’t know whether anyone at this organisation has actually used this technology — zero lived-experience observations exist.
Not yet answered
What are we missing?
HealthAratus Intelligence
Personalis
PersonalisPersonalis Intelligence
What the accumulated evidence, deployment record and lived experience actually show.
Intelligence lenses
Four ways of interrogating the same reality. Each changes the question, not the subject.
Do published findings about Personalis match what happens in practice?
Public evidence
Tempus to acquire Personalis for $1.5B
MobiHealthNews
Public evidence
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis
MedCity News
Public evidence
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
FierceHealthcare
What we know · what we don’t
Everything here is open to being corrected by someone who has seen it first-hand.
What we still don’t know
Nobody has answered these yet. Your experience can help us understand what is happening.
Matters of record
Settled elsewhere. Context for reading the above, not something practice can confirm.
- 3 public external signal(s) across 3 source(s).Recorded by HealthAratus
Tool intelligence
What HealthAratus understands
HealthAratus currently understands Personalis through deployment evidence, company records and external market activity.
- Category
- imaging_diagnostics
What HealthAratus is still learning
HealthAratus is beginning to understand Personalis. As evidence and experience accumulate, what remains unclear will be stated here.
Evidence & claims
What this is built on
The material the questions above were built from, with its attribution.
Personalis provides genomic testing services that analyze tumor exome and transcriptome data. Their platform monitors circulating tumor DNA to track cancer recurrence and immunotherapy response.According to Personalis
What Personalis states
The vendor’s own claims. Testable where practice can actually test them.
Stated capability
The assay detects circulating tumor DNA to monitor for cancer recurrence before traditional imaging.
According to Personalis
Does this change your workflow?
Independent and public evidence
Found in public sources. Not a clinician’s experience, and never presented as one.
Reported deployment
Tempus to acquire Personalis for $1.5B
According to MobiHealthNews
How widely is this actually used?
Reported deployment
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis
According to MedCity News
How widely is this actually used?
Reported deployment
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
According to FierceHealthcare
How widely is this actually used?
Company participation
Not yet verified
A record of the reality forming around this technology already exists. No representative of the company has verified participation yet.
Claim your company profileReference
The stable facts, for interpreting everything above.
Overview
What it does
-
Overview: Personalis, Inc. is a leader in advanced genomics for precision oncology, providing comprehensive tumor profiling and ultra-sensitive minimal residual disease (MRD) detection assays.
-
Technical Functionality: Personalis' NeXT Dx™ test analyzes a tumor's entire exome and transcriptome,…
Vendor & external product information, not independently verified by HealthAratus
Where it's used
Deployed in mixed settings
How the reality here has changed
Not enough recorded activity across time yet to describe how the reality here has moved. As accounts of Personalis accumulate, this becomes a record of how the reality moved rather than a snapshot of one moment.
Across the category
Personalis against the rest of Imaging & Diagnostics
Category intelligence reads this as Established. A sample of peers, not a census of the category.
Where Personalis may differ
Differences in what we have recorded. Never a ranking, never a quality judgement.
No first-hand account has been recorded for Personalis or for any peer we sampled in this category.
A gap across the whole category, not a fact about this technology.
Two readings that disagree
- Category intelligence reads clinical reality here as "Expanding", yet no first-hand account appears in the systems we sampled. Both readings are shown rather than reconciled.
Used another system in Imaging & Diagnostics? How does your experience compare?
A comparison across two systems tests the category, not just one product.
Connected intelligence
Category intelligence